



INDUSTRY SPONSORED SYMPOSIA

FRIDAY, MARCH 15, 2024



10:10-10:25	<p>Bayer Industry Sponsored Speakers' Corner</p> <p>Experience sustained disease control (SDC) with aflibercept 8mg in nAMD and DME Kenneth Fan, USA; Peter Kaiser, USA; John Kitchens, USA</p>	EXHIBITION AREA
-------------	--	------------------------



<p>12:15–13:15</p> <p>Chair:</p>	<p>Bayer Industry Sponsored Luncheon Symposium: A turning point in retinal care <i>(Lunch boxes served 12:00–12:15)</i></p> <p>Anat Loewenstein, Israel</p>	HALL A
12:15-12:20	<p>Welcome and introductions Anat Loewenstein, Israel</p>	
12:20-12:28	<p>Aflibercept’s unique MoA: rationale for a higher molar dose Peter Kaiser, USA</p>	
12:28-12:40	<p>A turning point in patient care: aflibercept 8mg in nAMD John Kitchens, USA</p>	
12:40-12:52	<p>A turning point in patient care: aflibercept 8mg in DME Sobha Sivaprasad, UK</p> <p>Navigating a diverse patient landscape: experience so far <i>Moderator: Anat Loewenstein, Israel</i> <i>Panelists/presenters:</i> Kenneth Fan, USA; Peter Kaiser, USA; John Kitchens, USA; Sobha Sivaprasad, UK</p>	
13:12-13:15	<p>Summary and close Anat Loewenstein, Israel</p>	

Friday, March 15, 2024 continued



13:25-13:40

Bayer Industry Sponsored Speakers' Corner

EXHIBITION
AREA

'A Chat with Anat': Are we entering a new era for patients and clinicians?

Anat Loewenstein, Israel; Tariq Aslam, UK

SATURDAY, MARCH 16, 2024



10:10-10:25

Bayer Industry Sponsored Speakers' Corner

EXHIBITION
AREA

A turning point in nAMD: incorporating aflibercept 8mg into clinical practice

Peter Kaiser, USA; John Kitchens, USA; Sobha Sivaprasad, UK



12:15-13:15

Evolve Industry Sponsored Luncheon Symposium:
Geographic Atrophy in the Age of Approved Therapy: Diagnosis, Clinical
Trial Data, and Real-World Treatment Approaches

HALL A

Supported by an educational grant from Astellas
(Lunch boxes served 12:00-12:15)

Panelists:

Anat Loewenstein, Israel; Baruch Kuppermann, USA; Jordi Monés, Spain

Diagnosis of GA in clinical settings

Prognosticating progression

Trial data for approved drugs

Real-world treatment decisions

Cases



13:30-14:30	Abbvie Industry Sponsored Dessert Symposium: The importance of inflammation and biomarkers in DME: a debate <i>(Dessert boxes served 13:15 - 13:30)</i>	HALL A
Chairs:	Anat Loewenstein, Israel; Baruch Kuppermann, USA	
13:30-13:35	Welcome and introductions Anat Loewenstein, Israel; Baruch Kuppermann, USA	
13:35-13:50	Role of Inflammation in DME Miltiadis Tsilimbaris, Greece	
13:50-14:09	Debate 1: Imaging biomarkers can reliably indicate inflammation in DME	
13:50-13:57	For: Irini Chatziralli, UK	
13:57-14:04	Against: Miltiadis Tsilimbaris, Greece	
14:04-14:09	Discussion and Q&A	
14:09-14:28	Debate 2: Early resolution of intraretinal fluid in DME is more likely to be achieved with steroid than with anti-VEGF	
14:09-14:16	For: Anat Loewenstein, Israel	
14:16-14:23	Against: Sobha Sivaprasad, UK	
14:23-14:28	Discussion and Q&A	
14:28-14:30	Close Anat Loewenstein, Israel; Baruch Kuppermann, USA	



14:40-14:55	Bayer Industry Sponsored Speakers' Corner A turning point in DME: implementing aflibercept 8mg in the clinic Peter Kaiser, USA; John Kitchens, USA; Sobha Sivaprasad, UK	EXHIBITION AREA
-------------	---	-----------------